A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer
Related Experiment Videos
J J Kavanagh1, C L Edwards, R S Freedman
1Section of Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy. A fundamental difficulty is the development of tumor resistance to platinum compounds. Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines. Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m2 but was later reduced to 40 mg/m2 because of excessive thrombocytopenia. Nine patients required red cell transfusions during therapy. Cycles were repeated every 21-35 days (median cycle length 28 days). No objective responses were observed. Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer.
Insights
Lobaplatin, a platinum compound, showed no effectiveness in treating platinum-resistant epithelial ovarian cancer. Further research into platinum-resistant ovarian cancer treatments is needed.
Area of Science:
- Oncology
- Pharmacology
Background:
- Epithelial ovarian cancer survival is poor due to platinum resistance.
- Developing new platinum analogs is crucial for overcoming treatment resistance.
Purpose of the Study:
- To evaluate the efficacy of lobaplatin in patients with platinum-refractory epithelial ovarian cancer.
Main Methods:
- Seventeen patients with platinum-refractory ovarian cancer received lobaplatin.
- Dosage was adjusted from 50 mg/m2 to 40 mg/m2 due to thrombocytopenia.
- Treatment cycles were administered every 21-35 days.
Main Results:
- No objective responses were observed in any patients.
- Significant toxicity, including thrombocytopenia requiring transfusions, was noted.
- Lobaplatin demonstrated no activity in this patient cohort.
Conclusions:
- Lobaplatin is ineffective against platinum-resistant epithelial ovarian cancer.
- New therapeutic strategies are required for managing platinum-refractory ovarian cancer.